Researchers from the University of Bern, Inselspital, University Hospital Bern, and the University of Connecticut have made a significant breakthrough in the fight against cancer. They identified a previously unknown weak point of prostate cancer cells. This could also lead to entirely new therapeutic approaches for other types of cancer.
Prostate cancer is the most common non-skin cancer in men worldwide. According to international estimates about one in six men will get prostate cancer during their lifetime and worldwide, over 375’000 patients will die from it each year. Tumor resistance to current therapies plays an essential role in this and new approaches are therefore urgently needed. Now an international research team from the University of Bern, Inselspital Bern and the University of Connecticut (USA) has identified a previously unknown weak spot in prostate cancer cells. This weak spot is possibly also present in other cancer cells. The study was led by Mark Rubin from the Department for Biomedical Research (DBMR) and Center for Precision Medicine (BCPM) at the University of Bern and Inselspital Bern, and Rahul Kanadia from the Department of Physiology and Neurobiology and the Institute for Systems Genomics at the University of Connecticut. The research results have now been published in the journal Molecular Cell.
Previously unknown driver of prostate cancer identified
“We took a closer look at a certain molecular machine called the spliceosome”, explains Anke Augspach, lead author of the study and researcher from the Department for BioMedical Research (DBMR). “It plays an important role in the translation of genes into proteins. In this process, the spliceosome separates parts of the gene that are not needed for the production of the protein and fuses the other parts.”
While almost all genes undergo this process in the so-called major spliceosome, the minor spliceosome is used in less than one percent of genes. “Nevertheless, the minor spliceosome is enormously important because it particularly processes genes that play a crucial role in cell growth. And it is this cell growth that gets out of control in cancer – but the precise mechanism behind this remained unclear”, explains Rahul Kanadia, study co-author from the Physiology and Neurobiology Department and the Institute for Systems Genomics at the University of Connecticut.
In their investigations, the team found various indications for the central role of the minor spliceosome in cancer. “We were able to show that a specific component of the minor spliceosome is significantly increased in advanced prostate cancer”, explains study co-author Mark Rubin of the Department for BioMedical Research (DBMR) and Bern Center for Precision Medicine (BCPM). This led the researchers to suspect that cancer cells activate the minor spliceosome through this component and thus stimulate uncontrolled cell growth.
An entirely new approach to cancer therapies
The researchers were able to confirm their assumption with the help of laboratory test models such as 2D cell cultures and organoids – miniature organs that are grown in the laboratory based on patient samples. They were also able to show that inhibiting the specific component led to a greater reduction in the growth of prostate cancer than current standard therapies. “Accordingly, blocking this process should hold therapeutic potential.”, Mark Rubin says. “This is the target that that we were hunting”. Rahul Kanadia adds that “The blocking leads to a decrease in cancer growth without affecting the growth and survival of normal cells.” “This discovery is a game changer in developing more effective and targeted combination therapies for cancers such as prostate cancer and other types of cancer. We want to work on this in the coming years – and have already applied for the corresponding patent”, Rubin concludes.
Research supported with 1 million dollars
The research results come from a project supported by the US Prostate Cancer Foundation (PCF) with the Igor Tulchinsky-Leerom Segal-PCF Challenge Award 2022. The foundation funds interdisciplinary projects that pursue promising approaches to combat recurrent or advanced prostate cancer. The award is endowed with 1 million dollars. “We commend the research team on their achievement and proudly support their work to bring us closer to our mission to eliminate death and suffering from prostate cancer”, says Howard R. Soule, Executive Vice President and Chief Science Officer of the PCF.
News
Brazilian Tree Compounds Fight COVID-19 on Multiple Fronts
Scientists found compounds in a Brazilian tree that hit SARS-CoV-2 on multiple fronts, revealing a promising new lead in the search for COVID-19 treatments. Researchers have found that galloylquinic acids extracted from the leaves [...]
Cutting Two Amino Acids Slowed Prostate Cancer in Mice
A newly identified link between amino acid metabolism and cholesterol production may help prostate tumors adapt to hormone therapy. Prostate cancer can find ways around treatments designed to deprive tumors of the hormones they [...]
Largest-Ever Physics Survey Raises New Doubts About Our Model of the Universe
Physicists around the world remain deeply divided on key mysteries of the universe, from dark matter to quantum gravity. The standard cosmological model failed to gain majority support, and no leading theory dominated the [...]
Scientists Just Overturned a 100-Year-Old Belief About Bacteria in the Lungs
New findings raise questions about the role of microbes living in the lungs. More than 35 trillion bacteria live throughout the human body, forming microbiomes in the gut, mouth, lungs, skin, and urogenital tract. [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
Novartis, Ionis drug failure spurs questions
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a result with important implications for cardiovascular drug research. Dive Brief: An RNA drug from [...]
New injectable treatment helps the brain rebuild after stroke
Biomedical engineers at Duke University have created an injectable biomaterial that may help the brain recover from damage left behind by an ischemic stroke. In experiments with mice, the material transformed the cavity created [...]
Scientists Discover a Hidden “Immune Organ” Inside the Skull
Researchers discovered lymph node-like immune hubs inside skull bone marrow that appear to act as rapid-response centers for the brain. For decades, the brain was thought to operate largely apart from the immune system. [...]
Engineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
Researchers have developed a potential new approach for treating a form of cystic fibrosis caused by so-called nonsense mutations, combining chemically modified transfer RNAs with lipid nanoparticles designed to deliver the therapy directly to [...]
New pancreatic cancer drug carries a $39,800 monthly list price
A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines’ oral tablet daraxonrasib, branded as Rasonque, reduced the risk of [...]
Researchers Have Discovered a New Way To Reduce Chronic Nerve Pain
A cancer-linked protein called BRAF may help drive chronic nerve pain, and existing cancer drugs targeting it reduced pain sensitivity in preclinical models. Chronic nerve pain can persist long after an injury and often [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Quantum-Enabled Regenerative Health: Reimagining Wellness, Precision Health and Longevity Medicine
Introduction Healthcare is approaching a frontier where the quantum portfolio could influence not only how disease is diagnosed and treated, but how health itself is measured, modeled, predicted and preserved. Quantum computing, quantum simulation, [...]
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option. Every day in the United States, approximately 17.5 veterans die by suicide, [...]
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
